Int J Med Sci 2022; 19(6):993-1002. doi:10.7150/ijms.73012 This issue Cite

Review

SIRT1: A Novel Protective Molecule in Pre-eclampsia

Zhenzhen Liu1,2, Chengjie Wang1,2, Jiangnan Pei1,2, Mingqing Li1,2✉, Weirong Gu1,2✉

1. Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China.
2. Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.

Citation:
Liu Z, Wang C, Pei J, Li M, Gu W. SIRT1: A Novel Protective Molecule in Pre-eclampsia. Int J Med Sci 2022; 19(6):993-1002. doi:10.7150/ijms.73012. https://www.medsci.org/v19p0993.htm
Other styles

File import instruction

Abstract

Graphic abstract

Pre-eclampsia is a severe pregnant complication, mainly characterized by insufficient trophoblast invasion, impaired uterine spiral artery remodeling, placental hypoxia and ischemia, and endothelial dysfunction. However, the potential mechanisms of pre-eclampsia remain unclear. SIRT1 is a NAD+-dependent deacetylase, involving in multiple biological processes, including energy metabolism, oxidative stress, inflammatory response, and cellular autophagy. Several studies showed that SIRT1 might play a vital role in the pathogenesis of pre-eclampsia. In this review, we aim to integrate the latest research on SIRT1 and pre-eclampsia to explore the comprehensive mechanisms of SIRT1 in pre-eclampsia. More specifically, SIRT1 might affect placental development and trophoblast invasion through autophagy and senescence in pre-eclampsia, and SIRT1 protects vascular endothelial cells from oxidative stress, inflammatory response, autophagy, and senescence. Furthermore, SIRT1 deficiency mice showed typical pre-eclampsia-like performances, which can be reversed via direct SIRT1 supplement or SIRT1 agonist treatment. Additionally, resveratrol, a SIRT1 agonist, attenuates vascular endothelial injury and placental dysfunction, and exerts protective effect on decreasing blood pressure. In this review, we provide new insights into the development of pre-eclampsia, which can establish a theoretical basis for prevention and treatment for pre-eclampsia. Besides, we also propose questions that still need to be further addressed in order to elucidate the comprehensive molecular mechanisms of pre-eclampsia in the future.

Keywords: pre-eclampsia (PE), SIRT1, trophoblasts, endothelial cells (ECs), resveratrol


Citation styles

APA
Liu, Z., Wang, C., Pei, J., Li, M., Gu, W. (2022). SIRT1: A Novel Protective Molecule in Pre-eclampsia. International Journal of Medical Sciences, 19(6), 993-1002. https://doi.org/10.7150/ijms.73012.

ACS
Liu, Z.; Wang, C.; Pei, J.; Li, M.; Gu, W. SIRT1: A Novel Protective Molecule in Pre-eclampsia. Int. J. Med. Sci. 2022, 19 (6), 993-1002. DOI: 10.7150/ijms.73012.

NLM
Liu Z, Wang C, Pei J, Li M, Gu W. SIRT1: A Novel Protective Molecule in Pre-eclampsia. Int J Med Sci 2022; 19(6):993-1002. doi:10.7150/ijms.73012. https://www.medsci.org/v19p0993.htm

CSE
Liu Z, Wang C, Pei J, Li M, Gu W. 2022. SIRT1: A Novel Protective Molecule in Pre-eclampsia. Int J Med Sci. 19(6):993-1002.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image